Visual field loss associated with vigabatrin: quantification and relation to dosage.

Area of Science:

• Neuroscience
• Ophthalmology
• Pharmacology

Background:

• Vigabatrin (VGB) is an antiepileptic drug used to treat certain types of seizures.
• Visual field defects are a known potential side effect of VGB therapy.
• Understanding the dose-response relationship is crucial for patient safety.

Purpose of the Study:

• To investigate the correlation between vigabatrin (VGB) dosage, duration, and total exposure with the extent of visual field loss.
• To assess the influence of co-medications and patient compliance on VGB-induced visual field deficits.

Main Methods:

• Ninety-two epilepsy patients with current or past VGB use were evaluated using Goldmann perimetry.
• Visual field loss was quantified using the Esterman grid and a novel percentage surface loss method.
• Drug history, including VGB and concomitant antiepileptic drugs (AEDs), was meticulously recorded; serum AED levels were determined.

Main Results:

• The total amount of VGB administered was the strongest predictor of visual field loss (p < 0.001).
• Male patients exhibited a significantly higher degree of visual field impairment compared to female patients (p = 0.026).
• Patient compliance was high, and co-administered AEDs did not significantly affect the observed visual field changes.

Conclusions:

• Prolonged vigabatrin (VGB) use is significantly correlated with the severity of visual field loss.
• VGB should be reserved for cases where alternative treatments are ineffective.
• Pre-treatment and regular 6-monthly peripheral visual field examinations are recommended for patients on VGB therapy.